(E/Z) -BCI

(E/Z) -BCI (NSC 150117) is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities. (E/Z) -BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway[1].

Product Specifications

CAS Number

[15982-84-0]

Product Name Alternative

NSC 150117

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H412

Target

Apoptosis; Phosphatase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/e-z-bci.html

Solubility

10 mM in DMSO

Smiles

O=C1/C(C(NC2CCCCC2)C3=C1C=CC=C3)=C\C4=CC=CC=C4

Molecular Formula

C22H23NO

Molecular Weight

317.42

Precautions

P264-P270-P273-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Zhang F, et al. DUSP6 Inhibitor (E/Z) -BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42 (2) :672-681.|[2]Wu QN, et al. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255.